0
0
A major investigation has revealed that as many as 300,000 women in the UK were prescribed a drug, known as Stilbestrol or DES (Diethylstilbestrol), intended to prevent miscarriages and halt breast milk production from the late 1930s to the late 1970s—years after mounting evidence had linked the drug to severe health risks including cancer.
Newly uncovered evidence shows the drug continued to be dispensed to pregnant women on the NHS nearly a decade after a ban should have stopped its use, raising urgent questions about past oversight and the protection of patients. Health Secretary Wes Streeting has now pledged that the government is “seriously” considering enhanced cancer screening for those affected and is investigating the circumstances that allowed this to happen.
A “Wonder Drug” With Devastating Consequences
Originally marketed as a wonder drug and synthetic oestrogen, DES was widely prescribed with the belief it could prevent miscarriage and, later, suppress breast milk production. However, over the years, scientific studies began linking DES to a heightened risk of several rare cancers, including breast, cervical, and vaginal cancers.
While the United States moved to ban DES in the 1970s following these findings, the UK continued its prescription much longer. ITV News reports that doctors, regulators, and successive governments repeatedly failed to act or alert women to the growing dangers, marking one of the NHS’s most significant pharmaceutical scandals.
Lasting Harm Passed Down Generations
Some women who were exposed to DES in the womb have endured “barbaric” medical complications, chronic pain, and a lifetime of surgeries as a result. Medical experts have further warned that the damage from DES may extend to subsequent generations, as the effects can be “passed down” and later generations may also face elevated health risks.
Calls are growing for official recognition, compensation, and specialist screening for those impacted, as many families continue to cope with the physical and emotional toll decades after the drug was last prescribed.
Official Response and Next Steps
The spotlight now falls on the UK government and health authorities, who are under pressure to act decisively after decades of inaction. Enhanced cancer screening is under consideration, and campaigners have renewed demands for a full inquiry, accountability, and financial support for victims.
“I want awareness, screening and compensation, because it’s taken some of my life away, and I can’t get that back,” said Suzanne Massey, one of many women now preparing to launch legal action after years of pain linked to DES exposure.
Disclaimer:
This article is based on ongoing investigations and public reports. Medical outcomes and potential risks described here may not apply universally, and readers should consult healthcare professionals for personal medical advice. The authorities are still reviewing historical evidence and policy decisions regarding DES; final conclusions and official recommendations may change as new information emerges.
